Treating Cognitive Deficits in Traumatic Spinal Cord Injury (SCI)
Treating Cognitive Deficits in Traumatic Spinal Cord Injury (SCI): A Randomized Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
West Orange, New Jersey, United States, 07052
- Kessler Foundation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- I am between the ages of 18 and 75 years old.
- I have a spinal cord injury with the level of injury between C1-T12.
- I am non-ambulatory (I use a wheelchair as my primary means of getting around).
- I have an AIS grade of A, B or C as determined by study staff examination.
- My injury occurred at least 1 year ago.
- My primary language is English.
Exclusion Criteria:
- I have a current illness or infection. My enrollment in this study can be delayed until my current illness or infection is successfully treated.
- I have any neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc.).
- I have a diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
- I have a history of Hypertension or Diabetes Mellitus (due to its impact on brain function).
- My vision is impaired- more than 20/60 in worst eye (with prescription eyewear).
- I have been taking steroids, benzodiazepines, or certain neuroleptics within past month, the study doctor will review my medications with me.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: memory experimental group
Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
|
Memory training twice a week for 5 weeks.
|
|
Placebo Comparator: Placebo comparator memory
Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
|
Placebo Memory training twice a week for 5 weeks
|
|
Experimental: Processing speed
Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
|
Speed training twice a week for 5 weeks.
|
|
Placebo Comparator: Processing speed placebo
Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
|
Placebo Speed training twice a week for 5 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
California Verbal Learning Test
Time Frame: Assessments will look at change over 6 weeks of treatment and 3 months after completion
|
California Verbal Learning TestPerformance on a memory test using the
|
Assessments will look at change over 6 weeks of treatment and 3 months after completion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SCI Quality of Life Scale
Time Frame: Assessments will look at change over 6 weeks of treatment and 3 months after completion
|
Reports on emotional functioning, memory functioning and quality of life using the SCI Quality of Life Scale, which measures all of these constructs.
DVs will be the depression subscale (range: 0-40; lower score is better) and cognitive subscale (range:0-40; higher score is better).
|
Assessments will look at change over 6 weeks of treatment and 3 months after completion
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symbol-Digit Modalities Test (oral form)
Time Frame: Assessments will look at change over 6 weeks of treatment and 3 months after completion
|
Performance on processing speed test, Symbol-Digit Modalities Test (oral form)
|
Assessments will look at change over 6 weeks of treatment and 3 months after completion
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Richard Green, PhD, Kessler Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Trauma, Nervous System
- Spinal Cord Diseases
- Wounds and Injuries
- Cognitive Dysfunction
- Cognition Disorders
- Spinal Cord Injuries
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
Other Study ID Numbers
Other Study ID Numbers
- R-947-16
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.